ClinicalTrials.gg
CompletedNCT02730377LIRA-PRIMEUpdated Jul 7, 2020Results posted

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

A Phase 4 interventional study of liraglutide and alpha-glucosidase inhibitors in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 232 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-07.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,991
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
2nd of 151
1,991 · median 62
Started
2016
with 11 others
Phase 4
48 of 151
1 open now
Registered
115th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 12 that started in 2016, is one of 48 in phase 4, and was the 115th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 1,991 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Male or female at least 18 years of age at the time of signing - Subjects diagnosed (clinically) with type 2 diabetes equal to or above 90 days prior to the screening visit - Stable daily dose of metformin as monotherapy equal to or above 1500 mg or maximum tolerated dose within 60 days prior to the screening visit - 7.5-9.0% (59-75 mmol/mol) (both inclusive) and measured within the last 90 days prior to the screening visit Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods (adequate contraceptive measures as required by local regulation or practice) - Treatment with any medication for the indication of diabetes other than metformin in a period of 60 days before the screening visit. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness - Receipt of any medicinal product within 30 days before the screening visit - Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,991 participants (actual)

Study arms

  • Experimental
    Liraglutide 1.8 mg

    Add-on to metformin

    Drug: liraglutide

  • Active comparator
    OAD

    Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.

    Drug: alpha-glucosidase inhibitors · Drug: DPP-4 inhibitors · Drug: meglitinides · Drug: SGLT-2 inhibitors · Drug: sulphonylurea · Drug: thiazolidinediones

Interventions

  • Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Drugmeglitinides

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Drugsulphonylurea

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

  • Drugthiazolidinediones

    Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

07

What researchers measure

Primary outcomes

  1. Time to Inadequate Glycaemic Control

    Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.

    Time frame: Weeks 26-104

Secondary outcomes

  1. Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)

    The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.

    Time frame: Weeks 0-104

  2. Change in HbA1c

    Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  3. Participants Who Achieve HbA1c ≤6.5% (Yes/No)

    Participants who achieved HbA1c ≤6.5% (yes/no) is presented.

    Time frame: Week 104/Premature treatment discontinuation

  4. Participants Who Achieve HbA1c ≤7.0% Without Weight Gain

    Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.

    Time frame: Week 104/Premature treatment discontinuation

  5. Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.

    Time frame: Week 104/Premature treatment discontinuation

  6. Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.

    Time frame: Week 104/Premature treatment discontinuation

  7. Change in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  8. Change in Body Weight

    Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  9. Change in Body Mass Index (BMI)

    Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  10. Change in Blood Pressure (Systolic and Diastolic Blood Pressure)

    Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  11. Number of Severe Hypoglycaemic Episodes

    Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.

    Time frame: Weeks 0-104

  12. Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.

    Time frame: Weeks 0-104

  13. Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)

    Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.

    Time frame: Weeks 0-104

  14. Number of Serious Adverse Events (SAEs)

    A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.

    Time frame: Weeks 0-105

  15. Number of AEs Leading to Permanent Discontinuation of Trial Product

    An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.

    Time frame: Weeks 0-105

  16. Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides

    Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  17. Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase

    Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  18. Change in Biochemistry- Creatinine, Total Bilirubin

    Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  19. Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum

    The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).

    Time frame: Week 0, week 104/premature treatment discontinuation

  20. Change in Potassium

    Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  21. Change in Haemoglobin

    Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

  22. Change in Pulse

    Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.

    Time frame: Week 0, week 104/premature treatment discontinuation

08

Results

Posted Jul 7, 2020

Participant flow

The trial was conducted at 219 sites in Canada (11), Colombia (3), India (16), Latvia (2), Lebanon (4), Russian Federation (5), Serbia (6), Turkey (4) and the United States (168).

Participant flow — Overall Study
MilestoneLiraglutide 1.8 mgOral Antidiabetic Drug
Started996995
Treated980984
Full analysis set (fas)996995
Safety analysis set (sas)980984
Completed446362
Not completed550633
Withdrew: Other54
Withdrew: Death18
Withdrew: Inadequate glycaemic control368473
Withdrew: Adverse event7941
Withdrew: Protocol violation2330
Withdrew: Lack of efficacy413
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject4542
Withdrew: Lost to follow-up2521

Outcome measures

PrimaryTime to Inadequate Glycaemic Control

Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.

Time frame:
Weeks 26-104
Reported as:
Median · Weeks
Time to Inadequate Glycaemic Control
WeeksLiraglutide 1.8 mgOral Antidiabetic Drug
Time to Inadequate Glycaemic Control108.9 (37.7 to NA)64.9 (35.4 to 107.4)
Statistical analysis
  • Liraglutide 1.8 mg vs Oral Antidiabetic Drug · Log Rank · p = <.0001
SecondaryTime to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)

The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.

Time frame:
Weeks 0-104
Reported as:
Median · Weeks
Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)
WeeksLiraglutide 1.8 mgOral Antidiabetic Drug
Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)80.4 (35.7 to NA)52.3 (35.1 to NA)
SecondaryChange in HbA1c

Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Percentage point of HbA1c
Change in HbA1c
Percentage point of HbA1cLiraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-1.4 ± 1.06-1.1 ± 1.04
Change at premature treatment discontinuation-0.6 ± 1.03-0.2 ± 1.56
SecondaryParticipants Who Achieve HbA1c ≤6.5% (Yes/No)

Participants who achieved HbA1c ≤6.5% (yes/no) is presented.

Time frame:
Week 104/Premature treatment discontinuation
Reported as:
Count of participants · Participants
Participants Who Achieve HbA1c ≤6.5% (Yes/No)
ParticipantsLiraglutide 1.8 mgOral Antidiabetic Drug
Yes255162
No741833
SecondaryParticipants Who Achieve HbA1c ≤7.0% Without Weight Gain

Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.

Time frame:
Week 104/Premature treatment discontinuation
Reported as:
Count of participants · Participants
Participants Who Achieve HbA1c ≤7.0% Without Weight Gain
ParticipantsLiraglutide 1.8 mgOral Antidiabetic Drug
Yes329234
No667761
SecondaryParticipants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes

Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.

Time frame:
Week 104/Premature treatment discontinuation
Reported as:
Count of participants · Participants
Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes
ParticipantsLiraglutide 1.8 mgOral Antidiabetic Drug
Yes388292
No608703
SecondaryParticipants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.

Time frame:
Week 104/Premature treatment discontinuation
Reported as:
Count of participants · Participants
Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
ParticipantsLiraglutide 1.8 mgOral Antidiabetic Drug
Yes320227
No676768
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
Millimoles per liter (mmol/L)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-2.2 ± 2.65-1.2 ± 2.46
Change at premature treatment discontinuation-0.6 ± 2.91-0.6 ± 3.76
SecondaryChange in Body Weight

Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Kilogram (Kg)
Change in Body Weight
Kilogram (Kg)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-3.8 ± 6.38-3.5 ± 6.19
Change at premature treatment discontinuation-2.9 ± 3.74-2.2 ± 4.93
SecondaryChange in Body Mass Index (BMI)

Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Kilograms per square meter (kg/m^2)
Change in Body Mass Index (BMI)
Kilograms per square meter (kg/m^2)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-1.3 ± 2.26-1.2 ± 2.14
Change at premature treatment discontinuation-1.1 ± 1.33-0.8 ± 1.71
SecondaryChange in Blood Pressure (Systolic and Diastolic Blood Pressure)

Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Millimeters of mercury (mmHg)Liraglutide 1.8 mgOral Antidiabetic Drug
SBP: Change at week 104-2.4 ± 15.09-1.1 ± 15.11
SBP: Change at premature treatment discontinuation-2.8 ± 15.99-2.9 ± 15.23
DBP: Change at week 104-1.3 ± 9.51-0.6 ± 9.54
DBP: Change at premature treatment discontinuation-1.0 ± 11.270.2 ± 9.69
SecondaryNumber of Severe Hypoglycaemic Episodes

Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.

Time frame:
Weeks 0-104
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes
EpisodesLiraglutide 1.8 mgOral Antidiabetic Drug
Number of Severe Hypoglycaemic Episodes3252
SecondaryNumber of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.

Time frame:
Weeks 0-104
Reported as:
Number · Episodes
Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesLiraglutide 1.8 mgOral Antidiabetic Drug
Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes2444
SecondaryNumber of Documented Symptomatic Hypoglycaemic Episodes (ADA)

Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.

Time frame:
Weeks 0-104
Reported as:
Number · Episodes
Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)
EpisodesLiraglutide 1.8 mgOral Antidiabetic Drug
Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)98155
SecondaryNumber of Serious Adverse Events (SAEs)

A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.

Time frame:
Weeks 0-105
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsLiraglutide 1.8 mgOral Antidiabetic Drug
Number of Serious Adverse Events (SAEs)145140
SecondaryNumber of AEs Leading to Permanent Discontinuation of Trial Product

An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.

Time frame:
Weeks 0-105
Reported as:
Number · Events
Number of AEs Leading to Permanent Discontinuation of Trial Product
EventsLiraglutide 1.8 mgOral Antidiabetic Drug
Number of AEs Leading to Permanent Discontinuation of Trial Product18898
SecondaryChange in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides

Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides
Millimoles per liter (mmol/L)Liraglutide 1.8 mgOral Antidiabetic Drug
HDL: Change at week 1040.1 ± 0.200.1 ± 0.19
HDL: Change at premature treatment discontinuation-0.0 ± 0.170.0 ± 0.20
LDL: Change at week 104-0.1 ± 0.800.0 ± 0.83
LDL: Change at premature treatment discontinuation-0.1 ± 0.68-0.1 ± 0.85
TC: Change at week 104-0.2 ± 0.920.1 ± 0.99
TC: Change at premature treatment discontinuation-0.0 ± 0.81-0.1 ± 0.96
TG: Change at week 104-0.3 ± 0.95-0.1 ± 1.25
TG: Change at premature treatment discontinuation-0.0 ± 1.13-0.0 ± 1.30
SecondaryChange in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase

Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Units per liter (U/L)
Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase
Units per liter (U/L)Liraglutide 1.8 mgOral Antidiabetic Drug
ALAT: Week 104-4.6 ± 17.83-5.4 ± 17.13
ALAT: Premature treatment discontinuation-3.2 ± 12.44-3.3 ± 14.67
Amylase: Week 1048.9 ± 30.935.1 ± 26.30
Amylase: Premature treatment discontinuation0.6 ± 23.612.1 ± 17.92
ASAT: Week 104-2.0 ± 13.27-2.3 ± 11.85
ASAT: Premature treatment discontinuation-1.9 ± 10.76-0.4 ± 11.64
Lipase: Week 10415.1 ± 67.69-0.5 ± 50.03
Lipase: Premature treatment discontinuation10.4 ± 32.40-2.2 ± 35.79
SecondaryChange in Biochemistry- Creatinine, Total Bilirubin

Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Micromoles per liter (umol/L)
Change in Biochemistry- Creatinine, Total Bilirubin
Micromoles per liter (umol/L)Liraglutide 1.8 mgOral Antidiabetic Drug
Creatinine: week 1043.3 ± 13.371.0 ± 12.86
Creatinine: premature treatment discontinuation2.9 ± 12.062.6 ± 21.13
TB: week 1040.4 ± 4.470.7 ± 3.80
TB: premature treatment discontinuation-0.0 ± 2.78-0.6 ± 3.17
SecondaryChange in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum

The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · mL/min/SSA
Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum
mL/min/SSALiraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-5.1 ± 20.33-1.6 ± 16.29
Change at premature treatment discontinuation-3.0 ± 12.56-1.7 ± 15.01
SecondaryChange in Potassium

Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in Potassium
Millimoles per liter (mmol/L)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-0.1 ± 0.60-0.0 ± 0.59
Change at premature treatment discontinuation-0.0 ± 0.44-0.2 ± 0.71
SecondaryChange in Haemoglobin

Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Grams per deciliter (g/dL)
Change in Haemoglobin
Grams per deciliter (g/dL)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 104-0.4 ± 1.07-0.0 ± 1.16
Change at premature treatment discontinuation-0.3 ± 0.87-0.3 ± 1.12
SecondaryChange in Pulse

Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.

Time frame:
Week 0, week 104/premature treatment discontinuation
Reported as:
Mean · Beats per minute (beats/min)
Change in Pulse
Beats per minute (beats/min)Liraglutide 1.8 mgOral Antidiabetic Drug
Change at week 1041.0 ± 10.25-0.6 ± 10.23
Change at premature treatment discontinuation0.7 ± 9.840.9 ± 10.59

Adverse events

Collected over Weeks 0-105. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 1.8 mg1/980 (0.1%)92/980 (9.4%)65/980 (6.6%)
Oral Antidiabetic Drug8/984 (0.8%)81/984 (8.2%)15/984 (1.5%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventLiraglutide 1.8 mgOral Antidiabetic Drug
Acute kidney injuryRenal and urinary disorders6/9802/984
Acute myocardial infarctionCardiac disorders5/9806/984
PneumoniaInfections and infestations4/9805/984
Angina pectorisCardiac disorders4/9801/984
Cerebrovascular accidentNervous system disorders4/9801/984
Chest painGeneral disorders4/9801/984
Cardiac failure congestiveCardiac disorders3/9804/984
Atrial fibrillationCardiac disorders3/9802/984
OsteoarthritisMusculoskeletal and connective tissue disorders3/9801/984
SepsisInfections and infestations0/9803/984
Most frequent other events
Most frequent other events
EventLiraglutide 1.8 mgOral Antidiabetic Drug
NauseaGastrointestinal disorders65/98015/984

Baseline characteristics

FAS included all randomised participants.

Age, Continuous
Age, Continuous(Years)Liraglutide 1.8 mgOral Antidiabetic DrugTotal
Mean57.6 ± 11.057.1 ± 10.757.4 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 1.8 mgOral Antidiabetic DrugTotal
Female476471947
Male5205241044
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liraglutide 1.8 mgOral Antidiabetic DrugTotal
Hispanic or Latino176189365
Not Hispanic or Latino8208061626
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Liraglutide 1.8 mgOral Antidiabetic DrugTotal
American Indian or Alaska Native369
Asian149141290
Black or African American101106207
Native Hawaiian or Other Pacific Islander325
White7247141438
Other162642
09

Study locations

232 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35211, United States
  • Novo Nordisk Investigational Site
    Haleyville, Alabama 35565-1719, United States
  • Novo Nordisk Investigational Site
    Tuscumbia, Alabama 35674, United States
  • Novo Nordisk Investigational Site
    Fountain Hills, Arizona 85268, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85018, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85037, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85050, United States
  • Novo Nordisk Investigational Site
    Tempe, Arizona 85283, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Harrisburg, Arkansas 72432-1132, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72212, United States
  • Novo Nordisk Investigational Site
    North Little Rock, Arkansas 72117, United States
  • Novo Nordisk Investigational Site
    Searcy, Arkansas 72143, United States
  • Novo Nordisk Investigational Site
    Alhambra, California 91801, United States
  • Novo Nordisk Investigational Site
    Buena Park, California 90620, United States
  • Novo Nordisk Investigational Site
    Carlsbad, California 92008, United States
  • Novo Nordisk Investigational Site
    Coronado, California 92118, United States
  • Novo Nordisk Investigational Site
    Costa Mesa, California 92627, United States
  • Novo Nordisk Investigational Site
    Elk Grove, California 95758, United States
  • Novo Nordisk Investigational Site
    Encinitas, California 92024, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92646, United States
  • Novo Nordisk Investigational Site
    La Mirada, California 90638, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Lomita, California 90717, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Oxnard, California 93030, United States
  • Novo Nordisk Investigational Site
    Rancho Cucamonga, California 91730-3063, United States
  • Novo Nordisk Investigational Site
    Riverside, California 92506, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92120, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94582, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Westminster, California 92683, United States
  • Novo Nordisk Investigational Site
    Centennial, Colorado 80012, United States
  • Novo Nordisk Investigational Site
    Centennial, Colorado 80112, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80906, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Monument, Colorado 80132, United States
  • Novo Nordisk Investigational Site
    Chiefland, Florida 32626, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33756, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32205, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33174, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33175, United States
  • Novo Nordisk Investigational Site
    Ocala, Florida 34470, United States
  • Novo Nordisk Investigational Site
    Ocoee, Florida 34761, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32819, United States
  • Novo Nordisk Investigational Site
    Ormond Beach, Florida 32174-6302, United States
  • Novo Nordisk Investigational Site
    Oviedo, Florida 32765, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684-3609, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Saint Petersburg, Florida 33713, United States
  • Novo Nordisk Investigational Site
    Seminole, Florida 33773, United States
  • Novo Nordisk Investigational Site
    Bainbridge, Georgia 39819, United States
  • Novo Nordisk Investigational Site
    Conyers, Georgia 30094-5965, United States
  • Novo Nordisk Investigational Site
    Perry, Georgia 31069, United States
  • Novo Nordisk Investigational Site
    Statesboro, Georgia 30461, United States
  • Novo Nordisk Investigational Site
    Suwanee, Georgia 30024, United States
  • Novo Nordisk Investigational Site
    Woodstock, Georgia 30189-4255, United States
  • Novo Nordisk Investigational Site
    Meridian, Idaho 83646, United States
  • Novo Nordisk Investigational Site
    Aurora, Illinois 60506, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60616, United States
  • Novo Nordisk Investigational Site
    Gillespie, Illinois 62033, United States
  • Novo Nordisk Investigational Site
    Wauconda, Illinois 60084, United States
  • Novo Nordisk Investigational Site
    Avon, Indiana 46123, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Greenfield, Indiana 46140, United States
  • Novo Nordisk Investigational Site
    Muncie, Indiana 47304, United States
  • Novo Nordisk Investigational Site
    Newton, Kansas 67114, United States
  • Novo Nordisk Investigational Site
    Park City, Kansas 67219, United States
  • Novo Nordisk Investigational Site
    Wichita, Kansas 67205, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Natchitoches, Louisiana 71457-5881, United States
  • Novo Nordisk Investigational Site
    Shreveport, Louisiana 71105, United States
  • Novo Nordisk Investigational Site
    Sunset, Louisiana 70584, United States
  • Novo Nordisk Investigational Site
    Elkridge, Maryland 21075-6437, United States
  • Novo Nordisk Investigational Site
    Oxon Hill, Maryland 20745, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Rochester, Michigan 48307, United States
  • Novo Nordisk Investigational Site
    Sterling Heights, Michigan 48310-3503, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Belzoni, Mississippi 39038, United States
  • Novo Nordisk Investigational Site
    Port Gibson, Mississippi 39150, United States
  • Novo Nordisk Investigational Site
    Butte, Montana 59701, United States
  • Novo Nordisk Investigational Site
    Missoula, Montana 59808, United States
  • Novo Nordisk Investigational Site
    Fremont, Nebraska 68025, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68144, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89118, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87108, United States
  • Novo Nordisk Investigational Site
    Brooklyn, New York 11215, United States
  • Novo Nordisk Investigational Site
    New Windsor, New York 12533, United States
  • Novo Nordisk Investigational Site
    North Massapequa, New York 11758-1802, United States
  • Novo Nordisk Investigational Site
    Westfield, New York 14787, United States
  • Novo Nordisk Investigational Site
    Asheboro, North Carolina 27203, United States
  • Novo Nordisk Investigational Site
    Burlington, North Carolina 27215, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28210, United States

Showing the first 100 of 232 sites across 10 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Unger J, Allison DC, Carlton M, Lakkole K, Lowe D, Murphy G, Panda JK, Sargin M, Kaltoft M, Treppendahl MB, Zoghbi M; LIRA-PRIME global panel. Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting. Diabetes Obes Metab. 2019 Jul;21(7):1543-1550. doi: 10.1111/dom.13682. Epub 2019 Mar 26. PubMed 30828917 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2019, 40 months.

Results were first posted in Jul 2020, 11 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 40 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Apr 6, 2016
StartActual
Mar 28, 2016
Primary completionActual
Aug 5, 2019
CompletionActual
Aug 12, 2019
Results first posted
Jul 7, 2020
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02730377
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 6, 2016
Start date
Mar 28, 2016
Primary completion
Aug 5, 2019
Completion
Aug 12, 2019
Results posted
Jul 7, 2020
Last update
Jul 7, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion